BIOSAFE, Inc. has announced that it has registered with the USEPA two new water-based antimicrobial solutions and entered into a commercialization agreement with Kentucky-based Union Springs Pharmaceuticals to market products containing BIOSAFE’s patented and exclusive antimicrobial polymer, HM4100. The unique and effective antimicrobial technology safely protects surfaces from harmful and degrading effects of bacteria, mold, mildew and fungi. HM4100 is approved for uses in a variety of substrates, including textiles, plastics, medical goods, construction and building products, and consumer products. This agreement gives Pittsburgh-based BIOSAFE greater access to the national and international marketplace, beginning with its first large order from Union Springs on December 6, 2010.
Union Springs offers MyClyns® (antimicrobial germ spray) and will offer products containing HM4100 under the MyClyns Antimicrobial Surface Treatments banner. HM4100 is a residual long-term antimicrobial that has proven its effectiveness against the proliferation of such bacteria as MRSA, VREF and Staph, along with mold, mildew and some influenza A viruses that include bird flu (H5N1) and swine flu (H1N1).
Part of the significance of the BIOSAFE solution is that it can be applied to both hard and porous surfaces, from tables, desks and counters, to bedding, clothing and carpeting.
“This agreement with Union Springs Pharmaceuticals and the launch of MyClyns products featuring our patented HM4100 antimicrobial is more than just a business venture,” said Max Fedor, CEO of BIOSAFE. ”The health protection benefits for millions of people around the world are potentially very significant. Thanks to this strategic alliance with Union Springs Pharmaceuticals, we will be able to build a strong market presence around our unique technology.”
Union Springs Pharmaceuticals plans to immediately market five new products containing HM4100, incorporating the antimicrobial treatment in sprays, surface wipes, fabric refreshers and as a laundry additive. Each of the new products will be launched in the first quarter of 2011. Following these steps, Union Springs plans to market additional products treated with HM4100.
“BIOSAFE continues to explore ways for further enhance the commercialization pipeline for HM4100,” said Mr. Fedor. ”The antimicrobial now has been approved by the United States EPA in both powder and liquid form, which improves scalability and distribution. To achieve this vision, BIOSAFE will work to form new strategic partnerships to grow into new geographic and vertical industry markets.”